Plasma clozapine and norclozapine in relation to prescribed dose and other factors in patients aged <18 years: data from a therapeutic drug monitoring service, 1994–2010

Clozapine is used in children and adolescents to treat early onset schizophrenia, but data on efficacy and on the plasma clozapine concentrations attained are limited.

[1]  J. Rapoport,et al.  Clozapine treatment of childhood-onset schizophrenia: evaluation of effectiveness, adverse effects, and long-term outcome. , 2007, Journal of the American Academy of Child and Adolescent Psychiatry.

[2]  N. Delva,et al.  Clozapine-Induced Seizures: Recognition and Treatment , 2007, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[3]  M. Swartz,et al.  Who are the new users of antipsychotic medications? , 2008, Psychiatric services.

[4]  H. Pandya,et al.  Dried blood spots, pharmacokinetic studies and better medicines for children. , 2011, Bioanalysis.

[5]  T. Mak,et al.  Plasma clozapine levels and clinical response in treatment-refractory Chinese schizophrenic patients , 2006, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[6]  Yeni Kim,et al.  Long‐term sustained benefits of clozapine treatment in refractory early onset schizophrenia: A retrospective study in Korean children and adolescents , 2008, Human psychopharmacology.

[7]  J. Rapoport,et al.  Clozapine use in children and adolescents. , 2008, Expert opinion on pharmacotherapy.

[8]  C. Correll.  Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients , 2008, International review of psychiatry.

[9]  Carmen Moreno,et al.  Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: Comprehensive review of prospective head-to-head and placebo-controlled comparisons , 2011, European Neuropsychopharmacology.

[10]  Sophia Frangou,et al.  Increased developmental deviance and premorbid dysfunction in early onset schizophrenia , 2003, Schizophrenia Research.

[11]  J. Rapoport,et al.  Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine. , 2002, Journal of child and adolescent psychopharmacology.

[12]  G. Cirulli.  Clozapine prescribing in adolescent psychiatry: survey of prescribing practice in in-patient units , 2005 .

[13]  M. Burke.  Principles of therapeutic drug monitoring. , 1981, Postgraduate medicine.

[14]  S. Kumra,et al.  Clozapine and “High-Dose” Olanzapine in Refractory Early-Onset Schizophrenia: A 12-Week Randomized and Double-Blind Comparison , 2008, Biological Psychiatry.

[15]  Matthias J. Müller,et al.  Therapeutic Monitoring of New Antipsychotic Drugs , 2004, Therapeutic drug monitoring.

[16]  B. Herpertz-Dahlmann,et al.  Weight gain in children and adolescents during 45 weeks treatment with clozapine, olanzapine and risperidone , 2008, Journal of Neural Transmission.

[17]  R. Lenroot,et al.  Treatment of early-onset schizophrenia , 2010, Current opinion in psychiatry.

[18]  B. Herpertz-Dahlmann,et al.  Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents , 2007, Journal of Neural Transmission.

[19]  J. Rapoport,et al.  Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine comparison. , 2006, Archives of General Psychiatry.

[20]  S. Preskorn,et al.  Examining Concentration-Dependent Toxicity of Clozapine: Role of Therapeutic Drug Monitoring , 2005, Journal of psychiatric practice.

[21]  A. Vourdas,et al.  The Maudsley early onset schizophrenia study. Predictors of psychosocial outcome at 4-year follow-up. , 2007, European child & adolescent psychiatry.

[22]  J. Rapoport,et al.  Childhood-onset schizophrenia: A double-blind clozapine-haloperidol comparison , 1996 .

[23]  S. Patten,et al.  Metabolic and Neurological Complications of Second-Generation Antipsychotic Use in Children , 2011, Drug safety.

[24]  S. Kapur,et al.  The Maudsley Prescribing Guidelines , 2009 .

[25]  I. Gillberg,et al.  Teenage psychoses--epidemiology, classification and reduced optimality in the pre-, peri- and neonatal periods. , 1986, Journal of child psychology and psychiatry, and allied disciplines.

[26]  B. Herpertz-Dahlmann,et al.  Clinical drug monitoring in child and adolescent psychiatry: side effects of atypical neuroleptics. , 2006, Journal of child and adolescent psychopharmacology.

[27]  Z. Dvořák,et al.  Valproic Acid Induces CYP3A4 and MDR1 Gene Expression by Activation of Constitutive Androstane Receptor and Pregnane X Receptor Pathways , 2007, Drug Metabolism and Disposition.

[28]  Amin Rostami-Hodjegan,et al.  Influence of Dose, Cigarette Smoking, Age, Sex, and Metabolic Activity on Plasma Clozapine Concentrations: A Predictive Model and Nomograms to Aid Clozapine Dose Adjustment and to Assess Compliance in Individual Patients , 2004, Journal of clinical psychopharmacology.

[29]  G. Tucker,et al.  Determination of drug-metabolizing enzyme activity in vivo: pharmacokinetic and statistical issues. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.

[30]  J. Rapoport,et al.  Decision making about children with psychotic symptoms: using the best evidence in choosing a treatment. , 2006, Journal of the American Academy of Child and Adolescent Psychiatry.

[31]  G. Dunn,et al.  Prevalence and nature of side effects during clozapine maintenance treatment and the relationship with clozapine dose and plasma concentration , 2007, International clinical psychopharmacology.

[32]  M. Fink.  EEG changes with antipsychotic drugs. , 2002, American Journal of Psychiatry.

[33]  S. Kumra,et al.  Clozapine versus "high-dose" olanzapine in refractory early-onset schizophrenia: an open-label extension study. , 2008, Journal of child and adolescent psychopharmacology.

[34]  Lewis Couchman,et al.  Plasma Clozapine, Norclozapine, and the Clozapine:Norclozapine Ratio in Relation to Prescribed Dose and Other Factors: Data From a Therapeutic Drug Monitoring Service, 1993–2007 , 2010, Therapeutic drug monitoring.

[35]  E. P. Spencer,et al.  Plasma Clozapine and Norclozapine in Patients Prescribed Different Brands of Clozapine (Clozaril, Denzapine, and Zaponex) , 2010, Therapeutic drug monitoring.

[36]  A. Watkins,et al.  Metabolic abnormalities in an early psychosis service: a retrospective, naturalistic cross‐sectional study , 2011, Early intervention in psychiatry.

[37]  Alessandro Zuddas,et al.  Antipsychotics in children and adolescents: Increasing use, evidence for efficacy and safety concerns , 2009, European Neuropsychopharmacology.

[38]  F. Carvalho,et al.  Haematological toxicity of clozapine and some other drugs used in psychiatry , 2011, Human psychopharmacology.

[39]  C. Panagiotopoulos,et al.  Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth. , 2011, Paediatrics & child health.

[40]  E. Spina,et al.  Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables. , 2008, Pharmacopsychiatry.

[41]  C. Correll,et al.  Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. , 2011, Journal of child and adolescent psychopharmacology.

[42]  G. Masi,et al.  Management of Schizophrenia in Children and Adolescents , 2011, Drugs.

[43]  Ann E. Maloney,et al.  Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. , 2008, The American journal of psychiatry.

[44]  R. Emsley.  New advances in pharmacotherapy for early psychosis , 2009, Early intervention in psychiatry.